Cargando…
Transgene distribution and immune response after ultrasound delivery of rAAV9 and PHP.B to the brain in a mouse model of amyloidosis
Efficient disease-modifying treatments for Alzheimer disease, the most common form of dementia, have yet to be established. Gene therapy has the potential to provide the long-term production of therapeutic in the brain following a single administration. However, the blood-brain barrier poses a chall...
Autores principales: | Kofoed, Rikke Hahn, Heinen, Stefan, Silburt, Joseph, Dubey, Sonam, Dibia, Chinaza Lilian, Maes, Miriam, Simpson, Elizabeth M., Hynynen, Kullervo, Aubert, Isabelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560718/ https://www.ncbi.nlm.nih.gov/pubmed/34761053 http://dx.doi.org/10.1016/j.omtm.2021.10.001 |
Ejemplares similares
-
rAAV-PHP.B escapes the mouse eye and causes lethality whereas rAAV9 can transduce aniridic corneal limbal stem cells without lethality
por: Mirjalili Mohanna, Seyedeh Zeinab, et al.
Publicado: (2023) -
Systemic AAV6-synapsin-GFP administration results in lower liver biodistribution, compared to AAV1&2 and AAV9, with neuronal expression following ultrasound-mediated brain delivery
por: Weber-Adrian, Danielle, et al.
Publicado: (2021) -
Pilot Study Assessing the Impact of Intrathecal Administration of Variants AAV-PHP.B and AAV-PHP.eB on Brain Transduction in Adult Rhesus Macaques
por: Arotcarena, Marie-Laure, et al.
Publicado: (2021) -
Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B
por: Jackson, Kasey L., et al.
Publicado: (2016) -
Corrigendum: Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B
por: Jackson, Kasey L., et al.
Publicado: (2016)